Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $3.00. The company’s shares closed last Friday at $1.57.
According to TipRanks, Olson is a 4-star analyst with an average return of 6.1% and a 39.92% success rate. Olson covers the Healthcare sector, focusing on stocks such as Amgen, Seagen, and Viking Therapeutics.
In addition to Oppenheimer, Nektar Therapeutics also received a Hold from Stifel Nicolaus’s Benjamin Burnett in a report issued on March 2. However, on February 24, Jefferies downgraded Nektar Therapeutics (NASDAQ: NKTR) to a Sell.
See the top stocks recommended by analysts >>
The company has a one-year high of $11.39 and a one-year low of $1.35. Currently, Nektar Therapeutics has an average volume of 1.96M.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NKTR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.
Read More on NKTR:
